摘要
目的探讨沙美特罗/丙酸氟替卡松吸入治疗稳定期中重度慢性阻塞性肺疾病(COPD)患者的临床疗效与安全性。方法将160例稳定期中重度COPD患者随机分为观察组和对照组,每组各80例。对照组予以常规治疗,观察组在对照组治疗的基础上吸入沙美特罗/丙酸氟替卡松干粉剂,规律治疗3个月,于治疗前、治疗过程中及治疗结束后分别观察圣.乔治呼吸疾病问卷(SGRQ)评分、6 min步行距离(6MWT)、肺功能指标及药物不良反应等。结果观察组70例、对照组63例获有效随访。治疗8周后,观察组与对照组均显示出一定的临床效果,2组SGRQ总分、6MWT、肺功能(FEV1及FEV1%Pred)、血气分析指标PaO2较治疗前均有改善(P均<0.05),血气分析指标PaCO2未见明显变化。2组治疗后SGRQ总分、6MWT、血气分析指标PaCO2、急性加重住院患者比例等比较,观察组优于对照组,差异均具有统计学意义(P均<0.05),肺功能(FEV1、FEV1%Pred)2组比较差异无统计学意义(P>0.05)。结论在常规诊疗措施的基础上,规律吸入沙美特罗/丙酸氟替卡松治疗稳定期中重度COPD具有较好的临床疗效和较高的临床安全性,适合于患者的长期、持续治疗。
Objective To explore the therapeutic effect and safety of salmeterol/fluticasone propionate powder inhalation on moderate or severe chronic obstructive pulmonary disease （COPD）. Methods A total of 160 patients with moderate or severe COPD at stable period were randomly divided into observation group and control group （ n = 80 each）. Patients in control group received routine therapy of COPD,yet patients in observation group received inhalation of salmeterol/flntieasone propionate dried powder on the basis of routine therapy. Patients in two groups were regularly treated for throe months. The st. George rospiratory questionnaire （SGRQ） mark,6-min walk test （6MWT）, pulmonary function indexes and drug adverse reactions before treatment,in treating process and after treatment were observed respectively. Results Seventy cases in observation group and 63 cases in control group were successfully followed up. All patients both in the observation group and in control group showed some clinical effects 8 weeks after treatment, the SGRQ total score,6MWT, FEV1 , FEV1 % prod, PaO2 were better than before treatment （ all P 〈0.05） ,yet there were no abvious changes in PaCO2 in blood gas analysis （ all P 〉0. 05）. Excluded FEV1 and FEV1% pred, the SGRQ total score,6MWT, PaO2 and the rate of hospitalization due to acute exacerbation in observation group were superior to those in control group （ all P 〈 O. 05 ）. Conclusions On top of conventional therapy, regular inhalation of salmeterol/fluticasone propionate powder has good clinical curative effect and high safety for treating moderate or severe COPD at stable period, and so it is suitable for long-term and sustained treatment.
出处
《中国临床研究》
CAS
2011年第11期974-976,共3页
Chinese Journal of Clinical Research
关键词
慢性阻塞性肺疾病
沙美特罗
丙酸氟替卡松
肺功能
Chronic obstructive pulmonary disease
Salmeterol
Fluticasone propionate
Pulmonary function
